The U.S. Wants to Bring the First Step of Human Testing Back Home, as Speed Becomes a New Battleground in Biotech Competition

The most critical moment in new drug competition is often not just before approval, but the moment the first human data emerge. Whoever can move a drug candidate into human testing faster, while still credibly, gains earlier signals on safety, dosing, and preliminary efficacy, and is also more likely to attract the next round of funding and licensing deals. The latest Operation TrialBlazer launched by the U.S. Department of Health and Human Services (HHS) puts this race for speed at the center of national biotech policy.

The reform was accompanied by a series of actions announced by the FDA on June 22, covering multiple stages from investigational new drug applications (INDs) to late-stage pivotal trials. On the early development side, the FDA proposed an accelerated IND pilot program for public comment, added a Phase 1 IND navigator webpage, updated Phase 1 chemistry, manufacturing, and controls (CMC) resources, established a Phase 1 contact center, and issued draft guidance on using quantitative systems pharmacology to support dose selection for first-in-human trials.

The core message of the reform is to recalibrate early review around what is “sufficient to protect participants,” rather than requiring companies to prepare a near-commercialization-level complete data package before Phase 1. The FDA said that if companies can more precisely understand phase-appropriate CMC requirements, they may save 6 to 12 months of development time. This is especially important for small biotech companies, which usually do not have the regulatory teams of large pharmaceutical companies and often submit excessive data to avoid a clinical hold, only to slow down the first human trial as a result.

On the late-stage trial side, the FDA also revised draft guidance on “substantial evidence of effectiveness” and master protocol trials. The former explains that, in certain circumstances, one adequate and well-controlled pivotal trial, together with confirmatory evidence, may be sufficient to support drug approval; the latter incorporates designs such as basket, umbrella, and platform trials, seeking to allow evidence to accumulate across multiple disease subtypes or multiple drug candidates under the same framework. These approaches do not amount to lowering the evidentiary threshold, but rather acknowledge that modern biology, data sources, and trial designs have changed.

The policy also carries a clear industrial strategy tone. The HHS roadmap states that China’s share of global Phase 1 trials surpassed that of the United States for the first time in 2021, and in 2024 China surpassed the United States with more than 7,100 registered clinical trials, accounting for about 39% of the global total. Reporting from the Foundation for Defense of Democracies interprets this as a step by the United States to catch up with China’s biotech sector; however, based on the official documents, HHS does not view China as the only competitor, and also mentions countries such as Australia that have attracted R&D investment with faster and clearer early trial processes.

Background Context

In recent years, the rapid increase in new drug licensing deals by Chinese biotech companies has led U.S. policy circles to worry that not only manufacturing supply chains, but also the earliest human evidence and intellectual property value, could accumulate overseas. HHS documents even state that global companies spent more than US$137 billion in 2025 licensing Chinese assets; but such figures come from market data cited in the policy roadmap and should be understood as signals of industry trends, rather than outcomes that a single reform can immediately reverse.

The real challenge is that speed and credibility cannot be discussed separately. If streamlining processes merely reduces duplicative paperwork and clarifies the data needed for Phase 1, both patients and innovators may benefit; but if regulators rely too heavily on flexible designs, alternative models, or fewer trials, they must explain more clearly what evidence is sufficient to support risk judgments. This is also the area where TrialBlazer most needs to be tested next: whether it can make U.S. clinical research faster while not turning rigor into a policy slogan.